221 related articles for article (PubMed ID: 11384863)
1. Ligands for the vitamin D endocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein.
Norman AW; Ishizuka S; Okamura WH
J Steroid Biochem Mol Biol; 2001; 76(1-5):49-59. PubMed ID: 11384863
[TBL] [Abstract][Full Text] [Related]
2. Molecular tools for study of genomic and rapid signal transduction responses initiated by 1 alpha,25(OH)(2)-vitamin D(3).
Norman AW; Bishop JE; Bula CM; Olivera CJ; Mizwicki MT; Zanello LP; Ishida H; Okamura WH
Steroids; 2002 May; 67(6):457-66. PubMed ID: 11960621
[TBL] [Abstract][Full Text] [Related]
3. Different shapes of the steroid hormone 1alpha,25(OH)(2)-vitamin D(3) act as agonists for two different receptors in the vitamin D endocrine system to mediate genomic and rapid responses.
Norman AW; Henry HL; Bishop JE; Song XD; Bula C; Okamura WH
Steroids; 2001; 66(3-5):147-58. PubMed ID: 11179722
[TBL] [Abstract][Full Text] [Related]
4. Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3.
Norman AW; Okamura WH; Bishop JE; Henry HL
Mol Cell Endocrinol; 2002 Nov; 197(1-2):1-13. PubMed ID: 12431790
[TBL] [Abstract][Full Text] [Related]
5. Minireview: vitamin D receptor: new assignments for an already busy receptor.
Norman AW
Endocrinology; 2006 Dec; 147(12):5542-8. PubMed ID: 16946007
[TBL] [Abstract][Full Text] [Related]
6. Differing shapes of 1 alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report.
Norman AW; Bishop JE; Collins ED; Seo EG; Satchell DP; Dormanen MC; Zanello SB; Farach-Carson MC; Bouillon R; Okamura WH
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):13-22. PubMed ID: 8603033
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D₃: genomic and non-genomic mechanisms.
Haussler MR; Jurutka PW; Mizwicki M; Norman AW
Best Pract Res Clin Endocrinol Metab; 2011 Aug; 25(4):543-59. PubMed ID: 21872797
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1 alpha,25-dihydroxyvitamin D3.
Swamy N; Xu W; Paz N; Hsieh JC; Haussler MR; Maalouf GJ; Mohr SC; Ray R
Biochemistry; 2000 Oct; 39(40):12162-71. PubMed ID: 11015194
[TBL] [Abstract][Full Text] [Related]
9. Characterization of five 19-nor-analogs of 1alpha,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains: implications for ligand binding and calcemic properties.
Olivera CJ; Bula CM; Bishop JE; Adorini L; Manchand P; Uskokovic MR; Norman AW
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):99-106. PubMed ID: 15225754
[TBL] [Abstract][Full Text] [Related]
10. The importance of stereochemistry on the actions of vitamin D.
Chiellini G; DeLuca HF
Curr Top Med Chem; 2011; 11(7):840-59. PubMed ID: 21291397
[TBL] [Abstract][Full Text] [Related]
11. Cytochromes P450 are essential players in the vitamin D signaling system.
Schuster I
Biochim Biophys Acta; 2011 Jan; 1814(1):186-99. PubMed ID: 20619365
[TBL] [Abstract][Full Text] [Related]
12. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands.
Carlberg C
Recent Results Cancer Res; 2003; 164():29-42. PubMed ID: 12899512
[TBL] [Abstract][Full Text] [Related]
13. Novel screening system for high-affinity ligand of heredity vitamin D-resistant rickets-associated vitamin D receptor mutant R274L using bioluminescent sensor.
Mano H; Nishikawa M; Yasuda K; Ikushiro S; Saito N; Sawada D; Honzawa S; Takano M; Kittaka A; Sakaki T
J Steroid Biochem Mol Biol; 2017 Mar; 167():61-66. PubMed ID: 27864003
[TBL] [Abstract][Full Text] [Related]
14. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
15. Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1alpha,25-dihydroxyvitamin D(3) receptor?
Mohr SC; Swamy N; Xu W; Ray R
Steroids; 2001; 66(3-5):189-201. PubMed ID: 11179726
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor 2016: novel ligands and structural insights.
Maestro MA; Molnár F; Mouriño A; Carlberg C
Expert Opin Ther Pat; 2016 Nov; 26(11):1291-1306. PubMed ID: 27454349
[TBL] [Abstract][Full Text] [Related]
17. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor.
Väisänen S; Peräkylä M; Kärkkäinen JI; Uskokovic MR; Carlberg C
Mol Pharmacol; 2003 Jun; 63(6):1230-7. PubMed ID: 12761332
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional model of the ligand binding domain of the nuclear receptor for 1alpha,25-dihydroxy-vitamin D(3).
Norman AW; Adams D; Collins ED; Okamura WH; Fletterick RJ
J Cell Biochem; 1999 Sep; 74(3):323-33. PubMed ID: 10412035
[TBL] [Abstract][Full Text] [Related]
19. Applications of the Vitamin D sterol-Vitamin D receptor (VDR) conformational ensemble model.
Mizwicki MT; Bishop JE; Norman AW
Steroids; 2005; 70(5-7):464-71. PubMed ID: 15862832
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
